Centrexion Therapeutics CNTX 深 滬
已收盤 10-10 16:00:00 美东时间
1.40
0.000
0.00%
華盛通- 最 高1.55
- 今 開1.47
- 成交量 93.37万股
- 最 低 1.35
- 昨 收 1.40
- 總市值 1.26亿
- 52周最高 2.5899
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 0.49
- 委 比 -97.70%
- 總股本 8970.42万
- 歷史最高 10.87
- 量 比 1.68
- 振 幅 14.29%
- 歷史最低 0.47
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced two posters will
10-06 19:38
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Context Therapeutics will present two posters at the Society for Immunotherapy of Cancer’s 40th Annual Meeting on November 7–9, 2025, in National Harbor, MD. The posters will highlight CT-95, a Phase 1 clinical trial targeting mesothelin in solid tumors, and preclinical data for CT-202, a pH-dependent TCE targeting Nectin-4. Both presentations will discuss the potential of these T cell engaging bispecific antibodies for treating various cancers.
10-06 11:30
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. granted stock options to purchase 30,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4), outside its 2021 Long-Term Performance Incentive Plan. The options, priced at $0.97 per share (October 1, 2025 closing price), have a 10-year term and vest over four years, with 25% vesting after the first year and the remainder in monthly installments. Context is a biopharmaceutical company advancing T cell engaging b...
10-03 20:15
Cantor Fitzgerald Initiates Coverage On Context Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.
10-02 20:40
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Guggenheim Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $5
Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $5.
09-18 21:02
Context Therapeutics Granted Nasdaq Extension for Compliance
Context Therapeutics ( ($CNTX) ) has shared an update. On August 28, 2025, Cont...
09-02 19:59
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. (Nasdaq: CNTX) announced its participation in two investor conferences: the Cantor Global Healthcare Conference 2025 on September 3 and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, both in New York. The company is advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio including CTIM-76, CT-95, and CT-202. Further details or meeting requests can be obtained via I...
08-27 11:30
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
08-22 12:00
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will release its Q2 2025 financial results and host a webcast/conference call on Monday, August 11, 2025, at 8:00 AM ET. The event will provide updates on the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. The call can be accessed via dial-in numbers 1-877-407-9716 (US) or 1-201-493-6779 (Intl.), using conference ID 13754...
08-08 20:01
